Riskpilot← Back to searchSign inGet full accessIncendia Pharma AB
ABActiveOrg 5593058729Economic activity was not specified by tax authority · NACE 0000Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
+45% vs 2023
Equity ratio
88.8%
Financial strength
Net profit 2024
SEK -12K
+45% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -12K | +45% |
| Net profit | SEK -12K | +45% |
| Total assets | SEK 178K | +5% |
| Equity | SEK 158K | +13% |
| Employees | 0 | — |
Legal name
Incendia Pharma AB
Org number
5593058729
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
8 mars 2021
Share capital
SEK 125 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning, utveckling, försäljning och licensiering av läkemedel och läkemedelssubstanser samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | −30 | −23 | −22 | −12 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | −30 | −23 | −22 | −12 |
| Net financials | — | — | — | — |
| Profit before tax | −30 | −23 | −22 | −12 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −30 | −23 | −22 | −12 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 155 | 162 | 170 | 178 |
| Equity | 125 | 132 | 140 | 158 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 30 | 30 | 30 | 20 |
| Total debt | 30 | 30 | 30 | 20 |
EBITDA margin
-1200000.0%
This company
15.8%
Market median
-7595037% vs market
20212024
Equity ratio
88.8%
This company
38.2%
Market median
+132% vs market
20212024
Return on equity
-7.6%
This company
18.4%
Market median
-141% vs market
20212024
Net profit margin
-1200000.0%
This company
8.1%
Market median
-14814915% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.13×
This company
0.62×
Market median
+79% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-03-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
NT Chief Executive Officer | Chief Executive Officer | 2022 |
KI Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 85% | 85% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
aXichem AB (publ)
Incendia Pharma AB Board members of Incendia Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Torsten Helsing | Chief Executive Officer | 0 companies |
| Karin Inger Annika Larsson | Chief Auditor | 0 companies |
| Jan-Ove Henry Gustavsson | Chairman | 0 companies |
| Gerd Ann Gunilla Savring | Board of Directors | 0 companies |